When was Sonomind founded?

Sonomind was founded in 2025 and raised its 1st funding round within a year of its incorporation.

Where is Sonomind located?

Sonomind is headquartered in France.

How many employees does Sonomind have?

As of Sep 30, 2026, the latest employee count at Sonomind is 19.

Is Sonomind a funded company?

Sonomind is a funded company, having raised a total of $25.8M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 24, 2025.

When was the latest funding round of Sonomind?

Sonomind's latest funding was a $***** Series A round on May 13, 2026, with participation from 2 investors.

Where does Sonomind rank among its competitors?

Sonomind ranks 11th amongst 46 active competitors, of which 10 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sonomind, which secured $23.5M in May, 2026.

Who are the top competitors of Sonomind?

Sonomind's top competitors include Freespira, Motif neurotech and NeuroSigma. Among them, Sonomind secured the most recent funding round in May, 2026.

Sonomind - 2026 Company Profile, Team, Funding & Competitors

Sonomind is a series A company based in France, founded in 2025 by Philippe Chapuis, Jeremy Bercoff, Jean-François Aubry, Mickaël Tanter and Thomas Tiennot. It operates as a Developer of a non-invasive therapeutic approach using ultrasound neuromodulation. Sonomind has raised $25.8M in funding from Bpifrance and Critical Path Ventures. The company has 46 active competitors, including 10 funded and 3 that have exited. Its top competitors include companies like Freespira, Motif neurotech and NeuroSigma.

Company Details

Developer of a non-invasive therapeutic approach using ultrasound neuromodulation. The technology aims for rapid and effective treatment for neuropsychiatric disorders. It focuses on precision targeting of deep brain regions. The technology relies on licensed software and expertise.

Key Metrics

Founded Year

2025

Location

France

Stage

Series A

Total Funding

$25.8M in 3 rounds

Latest Funding Round

Series A, May 13, 2026, $*****

Investors

Bpifrance & 1 more

Ranked

11^th among 46 active competitors

Employee Count

19 as on Sep 30, 2026

Similar Companies

Freespira & 58 more

View Sonomind's full profile

Sonomind has raised a total funding of $25.8M over 3 rounds. Its first funding round was on Sep 24, 2025. Its latest funding round was a Series A round on May 13, 2026 for $*****. 2 investors participated in its latest round. Sonomind has 2 institutional investors.

Here is the list of recent funding rounds of Sonomind:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2026	5166614	Series A	4201146	6842103	8571149	2809682
Sep 24, 2025	1964164	Grant (prize money)	2600850	5072084	1755817	Bpifrance
Sep 24, 2025	9417957	Seed	1313351	9303841	3686870	Critical Path Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Sonomind's funding rounds and investors

The founders of Sonomind are Philippe Chapuis, Jeremy Bercoff, Jean-François Aubry, Mickaël Tanter and Thomas Tiennot.

Here are the details of Sonomind's key team members:

Philippe Chapuis: Co-Founder & CTO of Sonomind.
Contact Info: 1 email address
Jeremy Bercoff: Co-Founder of Sonomind.
Contact Info: 1 email address
Jean-François Aubry: Co-Founder of Sonomind.
Mickaël Tanter: Co-Founder of Sonomind.
Thomas Tiennot: Co-Founder of Sonomind.
Contact Info: 1 email address

View details of Sonomind's Founder profiles and Board Members

Sonomind's employee count trend

Sonomind has 19 employees as of Sep 26. Here is Sonomind's employee count trend over the years:

Uncover Sonomind's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sonomind include Freespira, Motif neurotech and NeuroSigma. Here is the list of Top 10 competitors of Sonomind, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Freespira 2008, Danville (United States), Series D	Medical device & Mobile app to treat panic disorders	$48.9M	Lightspeed Venture Partners, Aphelion Capital ... & 4 others	60/100
2nd	Motif neurotech 2022, Houston (United States), Series A	Developer of minimally invasive bioelectronics for mental health disorders	$18.8M	Arboretum Ventures, Dolby Family Ventures ... & 9 others	60/100
3rd	NeuroSigma 2008, Los Angeles (United States), Seed	Develops and commercializes trigeminal nerve stimulation (TNS) devices for treatment of psychiatric disorders	$2.92M	Checkmate Capital, NINDS & 2 others	57/100
4th	Spark Biomedical 2018, Houston (United States), Series A	Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment	$31.2M	Wave Ventures, Wellcome Leap & 5 others	56/100
5th	Cervel 2008, Redwood City (United States), Acquired	Non-invasive neuromodulation through transcranial magnetic stimulation to treat treatment resistant depression	$23.6M	Aberdare Ventures, The D. E. Shaw Group & 1 others	47/100
6th	Nexalin 2010, Tustin (United States), Public	A non-invasive and drug free treatment for the treatment of anxiety, depression and insomnia	$502K	-	47/100
7th	Neuroelectrics 2011, Barcelona (Spain), Series A	Provider of wireless EEG monitoring and brain stimulation devices	$17.9M	Morningside, Intelectium & 3 others	43/100
8th	Rio Grande Neurosciences 2011, San Francisco (United States), Series A	Non-invasive brain stimulation therapies	$8.93M	-	41/100
9th	Thync 2011, Los Gatos (United States), Series B	Neuro-signaling headgear that changes state of mind	$13M	Khosla Ventures, Noosphere Ventures & 2 others	40/100
10th	Inner Cosmos 2017, Portola Valley (United States), Seed	Provider of AI-based device for treating mood and addiction disorders	$11.9M	Lool Ventures, Starlight Ventures & 5 others	39/100
11th	Sonomind 2025, France, Series A	Developer of a non-invasive therapeutic approach using ultrasound neuromodulation	$25.8M	Bpifrance, Critical Path Ventures	46/100